CSTL Fair Value Estimate
$28.4648.8% undervalued
Blended fair value estimate based on DCF, Graham Number, and earnings-based models.
Castle Biosciences Inc
Exchange: NASDAQSector: HealthcareIndustry: Diagnostics & Research
CASTELLE
Current Price
$19.13
+1.32%GoodMoat Value
$28.46
48.8% undervaluedProfile
Valuation (TTM)
Market Cap$568.76M
P/E-44.32
EV—
P/B1.21
Shares Out29.73M
P/Sales1.67
Revenue$339.92M
EV/EBITDA—
Castle Biosciences Inc (CSTL) Valuation
CSTL Valuation Metrics
FCF$28.37M
FCF Growth Rate29.28%
EPS Growth (CAGR)50.00%
WACC10.00%
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →CSTL Valuation & Fair Value Analysis
Castle Biosciences Inc (CSTL) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The GoodMoat Fair Value target for Castle Biosciences Inc is $28.46. The current stock price is $19.13, suggesting the stock is 48.8% undervalued.
The price-to-earnings (P/E) ratio is -44.32. Price-to-book ratio is 1.21. Price-to-sales ratio is 1.67. PEG ratio is 0.97.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Castle Biosciences Inc's intrinsic value.